Literature DB >> 23726178

Efficacy of the CHADS₂ scoring system to assess left atrial thrombogenic milieu risk before cardioversion of non-valvular atrial fibrillation.

Hirad Yarmohammadi1, Tristan Klosterman, Gaganpreet Grewal, M Chadi Alraies, Brandon C Varr, Bruce Lindsay, Andrew O Zurick, Kevin Shrestha, W H Wilson Tang, Mandeep Bhargava, Allan L Klein.   

Abstract

The CHADS₂ scoring system was found to be a good predictor for risk stratification of stroke in patients with atrial fibrillation. The effectiveness of this scoring system in assessing thrombogenic milieu before direct-current cardioversion has not yet fully been established on a large scale. In this study, data from 2,369 consecutive patients in whom transesophageal echocardiography was performed for screening before direct-current cardioversion from 1999 to 2008 were analyzed. Left atrial (LA) or LA appendage (LAA) thrombogenic milieu (spontaneous echo contrast, sludge, and thrombus) was investigated. The results were correlated with CHADS₂ score findings. The mean age was 66 ± 13 years, and the ratio of men to women was 2.2:1. CHADS₂ scores of 0, 1, 2, 3, 4, 5 and 6 were present in 11%, 25%, 30%, 22%, 8%, 3%, and 1% of the studies, respectively. The prevalence of LA or LAA sludge or thrombus increased with increasing CHADS₂ scores (2.3%, 7%, 8.5%, 9.9%, 12.3%, and 14.1% for scores of 0, 1, 2, 3, 4, and 5 or 6, respectively, p = 0.01). In a multivariate model, an ejection fraction ≤20% was the best predictor of LA or LAA sludge or thrombus (odds ratio 2.99, p <0.001). In conclusion, transesophageal echocardiographic markers of thrombogenic milieu were highly correlated with increasing CHADS₂ scores in patients who underwent transesophageal echocardiography-guided cardioversion. Giving more value to echocardiographic findings, such as the left ventricular ejection fraction, and its different levels (especially an ejection fraction ≤20%) might improve the precision of the CHADS₂ scoring scheme to predict thrombogenic milieu in the left atrium or LAA as a surrogate to cardioembolic risk in patients with atrial fibrillation.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23726178     DOI: 10.1016/j.amjcard.2013.04.047

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  9 in total

1.  Clinical outcomes after AF cardioversion in patients presenting left atrial sludge in trans-esophageal echocardiography.

Authors:  Fabien Squara; Mikael Bres; Didier Scarlatti; Pamela Moceri; Emile Ferrari
Journal:  J Interv Card Electrophysiol       Date:  2019-05-22       Impact factor: 1.900

2.  Growth differentiation factor 15 is associated with left atrial/left atrial appendage thrombus in patients with nonvalvular atrial fibrillation.

Authors:  Xiao Feng Hu; Rui Zhan; Shanhu Xu; Junjun Wang; Jiong Wu; Xiaoli Liu; Yaguo Li; Linhui Chen
Journal:  Clin Cardiol       Date:  2018-01-24       Impact factor: 2.882

3.  Left atrial thrombus formation and resolution during dabigatran therapy: A Japanese Heart Rhythm Society report.

Authors:  Hideo Mitamura; Takayuki Nagai; Atsuyuki Watanabe; Seiji Takatsuki; Ken Okumura
Journal:  J Arrhythm       Date:  2015-03-04

4.  Predicting Thromboembolic and Bleeding Event Risk in Patients with Non-Valvular Atrial Fibrillation: A Systematic Review.

Authors:  Ethan D Borre; Adam Goode; Giselle Raitz; Bimal Shah; Angela Lowenstern; Ranee Chatterjee; Lauren Sharan; Nancy M Allen LaPointe; Roshini Yapa; J Kelly Davis; Kathryn Lallinger; Robyn Schmidt; Andrzej Kosinski; Sana M Al-Khatib; Gillian D Sanders
Journal:  Thromb Haemost       Date:  2018-10-30       Impact factor: 6.681

5.  Association of CHADS2 and CHA2DS2-VASc Scores with Left Atrial Thrombus with Nonvalvular Atrial Fibrillation: A Single Center Based Retrospective Study in a Cohort of 2695 Chinese Subjects.

Authors:  J Huang; S L Wu; Y M Xue; H W Fei; Q W Lin; S Q Ren; H T Liao; X Z Zhan; X H Fang; L Xu
Journal:  Biomed Res Int       Date:  2017-03-08       Impact factor: 3.411

6.  Non-cardioembolic risk factors in atrial fibrillation-associated ischemic stroke.

Authors:  Pil-Sung Yang; Hui-Nam Pak; Dong-Hyuk Park; Joonsang Yoo; Tae-Hoon Kim; Jae-Sun Uhm; Young Dae Kim; Hyo Suk Nam; Boyoung Joung; Moon-Hyoung Lee; Ji Hoe Heo
Journal:  PLoS One       Date:  2018-07-20       Impact factor: 3.240

Review 7.  Diagnosis and Management of Left Atrium Appendage Thrombosis in Atrial Fibrillation Patients Undergoing Cardioversion.

Authors:  Enrico Melillo; Giuseppe Palmiero; Adele Ferro; Paola Elvira Mocavero; Vittorio Monda; Luigi Ascione
Journal:  Medicina (Kaunas)       Date:  2019-08-21       Impact factor: 2.430

8.  Determinants of left atrium thrombi in scheduled cardioversion: an ENSURE-AF study analysis.

Authors:  Jose L Merino; Gregory Y H Lip; Hein Heidbuchel; Aron-Ariel Cohen; Raffaele De Caterina; Joris R de Groot; Michael D Ezekowitz; Jean-Yves Le Heuzey; Sakis Themistoclakis; James Jin; Michael Melino; Shannon M Winters; Béla Merkely; Andreas Goette
Journal:  Europace       Date:  2019-11-01       Impact factor: 5.214

9.  Use of the CHA2DS2VASc score to reduce utilisation of transoesophageal echocardiography prior to ablation for atrial fibrillation.

Authors:  Charlotte Atkinson; Jonathan Hinton; Edmund B Gaisie; Arthur M Yue; Paul R Roberts; Dhrubo J Rakhit; Benoy N Shah
Journal:  Echo Res Pract       Date:  2017-09-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.